Prevention of bleeding in hemophilia patients with high-titer inhibitors
Leissinger, Cindy A.
Konkle, Barbara A.
Antunes, Sandra V. [UNIFESP]
Is part ofExpert Review of Hematology
MetadataShow full item record
Inhibitor development is the most serious adverse event linked to the treatment of hemophilia, as it renders standard hemostatic therapy ineffective. Consequently, inhibitor patients are at increased risk for difficult-to-control bleeding and complications, particularly arthropathy and physical disability. Three randomized clinical trials in patients with inhibitors have demonstrated that compared with on-demand bypassing therapy, prophylaxis with a bypassing agent reduces joint and other types of bleeding and improves health-related quality of life. in hemophilia patients without inhibitors, the initiation of prophylaxis with factor (F) VIII or IX prior to the onset of recurrent hemarthroses can prevent the development of joint disease. Whether this is also true for bypassing agent prophylaxis remains to be determined.
CitationExpert Review of Hematology. London: Expert Reviews, v. 8, n. 3, p. 375-382, 2015.
Keywordsactivated prothrombin complex concentrate
recombinant activated factor VII
Baxter Healthcare Corp
- EPM - Outras produções